Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TP-04 (lotilaner)
- Development stage
- Unknown
- Lead developer
- Tarsus Pharmaceuticals
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical, Ophthalmic
01
Overview
TP-04 is an investigational, sterile, topical ophthalmic gel formulation of lotilaner being developed by Tarsus Pharmaceuticals for the treatment of ocular rosacea and papulopustular rosacea. Lotilaner is a well-characterized antiparasitic agent that paralyzes and kills mites—particularly *Demodex* mites—by selectively inhibiting parasite-specific GABA-chloride channels. This mechanism targets the underlying parasitic cause believed to contribute to inflammatory conditions such as ocular rosacea and papulopustular rosacea. TP-04 represents a potential category-creating therapy in areas with high unmet need, as there are currently no FDA-approved therapies specifically for ocular rosacea.
- Other names
- lotilaner ophthalmic gel
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR6 (5-hydroxytryptamine receptor 6)DAT (Dopamine plasma membrane transport protein)RDL (Insect GABA-gated chloride channel)GluCl (Glutamate-gated chloride channel)MTNR1A (MT1)NET (Norepinephrine Transporter)σR (Sigma receptors)TACR2 (Neurokinin-2 Receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on TP-04 (lotilaner).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TP-04 (lotilaner).